Novo Nordisk AS Class B NONOF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Beleaguered Novo offers relief to investors, thanks to Wegovy pill
Novo Nordisk Lifts Outlook as Rollout of Wegovy Weight-Loss Pill Continues — Update
Novo Nordisk Lifts Guidance as Rollout of Wegovy Weight-Loss Pill Continues
Stock Spotlight
GLP-1 drugs could ease back and knee pain, but doctors say there are risks for older adults
Novo Nordisk Says FDA Review of Hemophilia Drug Is Hitting Delays
Eli Lilly Says Zepbound Delivers Greater Weight Loss Than Higher-Dose Version of Novo's Wegovy
Taking Ozempic and worried about vision loss? This test can help you understand your risk.
Trading Information
- Previous Close Price
- $42.36
- Day Range
- $39.72–41.08
- 52-Week Range
- $34.00–62.75
- Bid/Ask
- $30.00 / $69.82
- Shares Outstanding
- 4.41B
- Market Cap
- $178.70B
- Volume/Avg
- 434,178 / 102,597
Key Statistics
- Price/Earnings (Normalized)
- 9.40
- Price/Sales
- 3.63
- Dividend Yield (Trailing)
- 4.25%
- Dividend Yield (Forward)
- 4.25%
- Dividend Payment Schedule
- Mar, Aug
- Total Yield
- 5.07%
Company Profile
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 68,794
- Website
- https://www.novonordisk.com
Competitors
Valuation
Metric | NONOF | RHHBY | SNY |
|---|---|---|---|
Price/Earnings (Normalized) | 9.40 | 21.06 | 12.30 |
Price/Book Value | 5.66 | 9.60 | 1.38 |
Price/Sales | 3.63 | 4.95 | 1.93 |
Price/Cash Flow | 9.54 | 15.49 | 8.25 |
Price/Earnings
NONOF
RHHBY
SNY
Financial Strength
Metric | NONOF | RHHBY | SNY |
|---|---|---|---|
Quick Ratio | 0.63 | 0.80 | 0.21 |
Current Ratio | 0.84 | 1.23 | 1.12 |
Interest Coverage | — | 13.49 | 9.10 |
Quick Ratio
NONOF
RHHBY
SNY
Profitability
Metric | NONOF | RHHBY | SNY |
|---|---|---|---|
Return on Assets (Normalized) | 20.15% | 15.81% | 8.44% |
Return on Equity (Normalized) | 56.25% | 48.77% | 15.62% |
Return on Invested Capital (Normalized) | 33.34% | 23.90% | 12.02% |
Return on Assets
NONOF
RHHBY
SNY
Drug Manufacturers - General Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Eli Lilly and Co LLY | LOCK|Pjf^L>? | LOCK|%X | $1T | |||
| Johnson & Johnson JNJ | LOCK|WnqQ!sP | LOCK|jM | $665B | |||
| AbbVie Inc ABBV | LOCK|$?@Drd@ | LOCK|Rk | $521B | |||
| Roche Holding AG ADR RHHBY | LOCK|hT!&LgrW | LOCK|ZZ | $386B | |||
| Merck & Co Inc MRK | LOCK|G^&@Qc% | LOCK|q& | $371B | |||
| Novartis AG ADR NVS | LOCK|%JK^?@l | LOCK|T@ | $309B | |||
| AstraZeneca PLC AZN | LOCK|chL&$>$h | LOCK|sP | $292B | |||
| Amgen Inc AMGN | LOCK|whY?#K> | LOCK|f% | $259B | |||
| Gilead Sciences Inc GILD | LOCK|V&m^#pM | LOCK|%p | $216B | |||
| Novo Nordisk AS ADR NVO | LOCK|SwHl%cr | LOCK|gV | $189B |
United States